Corvus Pharmaceuticals, Inc.
NASDAQ: CRVS0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Richard A. Miller
- Employees
- 31
- Headquarters
- South San Francisco, United States
- IPO year
- 2016
- Market cap
- $1.1B
- Website
- https://www.corvuspharma.com
Loading CRVS…
Loading profile data…Frequently asked questions about CRVS
What does Corvus Pharmaceuticals, Inc. (CRVS) do?
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm specializing in the development and commercialization of immuno-oncology therapies. Their leading investigational compound, Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, is currently progressing through Phase Ib/II clinical trials for the treatment of non-small ce...
Where does CRVS trade?
Corvus Pharmaceuticals, Inc. (CRVS) trades on the NASDAQ Global Market.
What sector is CRVS in?
Corvus Pharmaceuticals, Inc. (CRVS) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Corvus Pharmaceuticals, Inc.?
Richard A. Miller is the chief executive officer of Corvus Pharmaceuticals, Inc. (CRVS).
Where is Corvus Pharmaceuticals, Inc. headquartered?
Corvus Pharmaceuticals, Inc. is headquartered in United States.
Does CRVS pay a dividend?
Corvus Pharmaceuticals, Inc. (CRVS) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did CRVS go public?
Corvus Pharmaceuticals, Inc. (CRVS) completed its initial public offering in 2016.